Itamoto T, Asahara T, Katayama K, Nakahara H, Fukuda T, Yano M, Hino H, Nakahara M, Dohi K, Shimamoto F
Department of Surgery II, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-Ku, Hiroshima, Japan.
Hepatogastroenterology. 2001 Jul-Aug;48(40):1129-33.
BACKGROUND/AIMS: The aim of this study was to investigate the clinicopathologic features and biological behaviors related to the gross appearance of intrahepatic cholangiocarcinoma.
Fourteen patients with intrahepatic cholangiocarcinoma who underwent hepatic resection between 1986 and 1998 were divided into four groups according to the gross appearance of the tumor: ID (intraductal growth) type (n = 1), PD (periductal-infiltrating) type (n = 4), MF (mass-forming) type (n = 5), MF-with-PD type (n = 4).
Overall survival at 1, 5, and 10 years was 50.0%, 35.7%, and 35.7%, respectively. All three long-term survivors without recurrence had tumors unassociated with vascular invasion, intrahepatic metastasis, or lymph node metastasis. The MF and MF-with-PD tumors were more frequently associated with vascular invasion and/or lymph node metastasis than the ID or PD type. The Ki-67-positive grade of the cancer cells was clearly higher in the MF and MF-with-PD tumors than in the ID or PD type. All of the cases of MF-with-PD tumors were stage IV-A and had a poor outcome.
Extended hepatic resection with a sufficient surgical margin yielded good results in intrahepatic cholangiocarcinoma patients without vascular invasion, intrahepatic metastasis, or lymph node metastasis. However, it is necessary to develop a new effective strategy for advanced intrahepatic cholangiocarcinomas, such as the MF-with-PD type.
背景/目的:本研究旨在探讨肝内胆管癌大体外观相关的临床病理特征及生物学行为。
对1986年至1998年间接受肝切除术的14例肝内胆管癌患者,根据肿瘤大体外观分为四组:导管内生长(ID)型(n = 1)、导管周围浸润(PD)型(n = 4)、肿块形成(MF)型(n = 5)、MF伴PD型(n = 4)。
1年、5年和10年总生存率分别为50.0%、35.7%和35.7%。所有3例无复发的长期存活者的肿瘤均与血管侵犯、肝内转移或淋巴结转移无关。MF和MF伴PD肿瘤比ID或PD型更常伴有血管侵犯和/或淋巴结转移。MF和MF伴PD肿瘤中癌细胞的Ki-67阳性分级明显高于ID或PD型。所有MF伴PD肿瘤病例均为IV-A期,预后较差。
对于无血管侵犯、肝内转移或淋巴结转移的肝内胆管癌患者,行切缘充分的扩大肝切除术可取得良好效果。然而,有必要为晚期肝内胆管癌,如MF伴PD型,制定新的有效策略。